Oncology

Front Line Therapy in Non-Small Cell Lung Cancer

Source: 9th European Congress: Perspectives in Lung Cancer, Torino, Italy, March 14-15, 2008
Nick Thatcher
Nick Thatcher

NICK THATCHER, Christie Hospital, Manchester
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.

Download this interview

Similar Interviews

  • Audio Journal of Oncology 12.7, September 2004
  • Reporting from: - 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 - New England Journal

  • Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
  • Robert Pirker ROBERT PIRKER , Medical University of Vienna Phase III study results have

  • Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
  • Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin

    Post a comment